Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Caffeine Contributes to Development of Diabetes

By HospiMedica International staff writers
Posted on 19 Apr 2011
A new review article contradicts earlier studies suggesting a protective effect of caffeine against type 2 diabetes mellitus (T2DM). More...


James Lane, PhD, a researcher at Duke University Medical Center (Durham, NC, USA) reviewed a growing body of evidence that suggests that consumption of caffeine leads to disruptions of glucose metabolism, which could be of concern for both the development of T2DM and its clinical management. At least 17 studies have consistently demonstrated that caffeine administration in healthy, nondiabetic adults produces an acute increase in insulin resistance or impairment of glucose tolerance, an effect that could contribute to T2DM disease progression in susceptible individuals.

Other studies of coffee drinkers who have T2DM have found that caffeine exaggerates the rise in glucose after carbohydrate ingestion, an effect that could contribute to higher chronic glucose levels and impaired clinical control. The results of these well-controlled experimental studies contradict epidemiological studies that find that heavy coffee drinking is associated with a lower risk of T2DM. Dr. Lane concluded that although it is premature to recommend caffeine abstinence for patients with T2DM and for those at risk, the evidence is sufficient to warrant further study of caffeine's effects, including clinical trials of the potential benefits of eliminating caffeine from the diet. The review was published in March 2011 inaugural issue of Journal of Caffeine Research.

"The links that have been revealed between diabetes and the consumption of caffeine beverages (especially coffee) are of monumental importance when it is acknowledged that more than 80% of the world's population consumes caffeine daily,” said editor-in-chief of the new journal Jack James, PhD, of the school of psychology at the University of Ireland (Galway). "Dr. Lane's review of the topic gives the clearest account to date of what we know, what we don't know, and what needs to be done - urgently!”

Caffeine is a bitter, white crystalline xanthine alkaloid that is a psychoactive stimulant but unlike many other psychoactive substances, it is unregulated in nearly all jurisdictions. In humans, caffeine acts as a central nervous system (CNS) stimulant, temporarily warding off drowsiness and restoring alertness.

Related Links:
Duke University Medical Center
University of Ireland



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.